Lundbeck set for US launch of blockbuster drug  

H Lundbeck is close to gaining approval in the US for its new antidepressant Lexepro

Berlingske Tidende Online reports today that Danish pharmaceutical company H. Lundbeck's new SSRI antidepressant Lexepro (escitalopram), already launched in UK, is close to gaining US approval. According to the Wall Street Journal, the new drug is likely to prove a blockbuster due to its reportedly minimal side effect profile. One in ten US citizens suffers from depression and around 10 million take antidepressants, making it the next largest treatment area after antibiotics.


Lexepro will be marketed in the US by Forrest Laboratories, which has just extended its sales force from 1,500 to 2,100. Lexepro is the successor to H. Lundbeck's highly successful antidepressant Celexa (citalopram), and market analysts expect that the combined sales of both drugs in the US will increase by around 50%.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×